The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial

The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and microbial translocation (MT), has not been established in a...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-12, Vol.9 (12), p.e116306
Main Authors: Somsouk, Ma, Dunham, Richard M, Cohen, Michelle, Albright, Rebecca, Abdel-Mohsen, Mohamed, Liegler, Teri, Lifson, Jeffrey, Piatak, Michael, Gorelick, Robert, Huang, Yong, Wu, Yuaner, Hsue, Priscilla Y, Martin, Jeffrey N, Deeks, Steven G, McCune, Joseph M, Hunt, Peter W
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
Activation
AIDS
Antiretroviral agents
Antiretroviral drugs
Antiretroviral therapy
Biology and life sciences
Biomarkers - metabolism
Biomedical research
Brachial Artery - drug effects
Brachial Artery - physiopathology
Cancer
Cardiovascular Diseases - immunology
Cardiovascular Diseases - physiopathology
Cardiovascular Diseases - virology
CD38 antigen
CD4 antigen
CD4-Positive T-Lymphocytes - drug effects
CD4-Positive T-Lymphocytes - immunology
CD8 antigen
Clinical trials
Comparative analysis
Cross-Over Studies
Drug therapy
Female
Follow-Up Studies
Gastroenterology
Health aspects
Highly active antiretroviral therapy
Histocompatibility antigen HLA
HIV
HIV infections
HIV Infections - drug therapy
HIV Infections - immunology
Human immunodeficiency virus
Humans
Infections
Inflammation
Inflammation - pathology
Inflammatory bowel disease
Inflammatory bowel diseases
Interleukin 6
Laboratories
Lymphocyte Activation - immunology
Lymphocytes
Lymphocytes T
Male
Medicine
Medicine and Health Sciences
Mesalamine
Mesalamine - adverse effects
Mesalamine - pharmacology
Mesalamine - therapeutic use
Microorganisms
Middle Aged
Mortality
Mucosal immunity
Peripheral blood
Randomization
Recovery (Medical)
Rectum
Rectum - pathology
Ribonucleic acid
RNA
Solubility
T cells
Translocation
Tryptophan
Ulcerative colitis
Vasodilation - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and microbial translocation (MT), has not been established in a placebo-controlled trial. We randomized 33 HIV-infected subjects with CD4 counts
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0116306